Dourthe ME, Bolle S, Temam S, Jouin A, Claude L, Reguerre Y, et al. Childhood nasopharyngeal carcinoma: state-of-the-art, and questions for the future. J Pediatr Hematol Oncol. 2018;40(2):85–92.
Article
Google Scholar
Sultan I, Casanova M, Ferrari A, Rihani R, Rodriguez-Galindo C. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer. 2010;55(2):279–84.
Article
Google Scholar
Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;18(7):873–98.
Article
Google Scholar
Peng H, Chen L, Zhang Y, Li WF, Mao YP, Zhang F, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective phase III clinical trial. Oncologist. 2016;21(11):1369–76.
Article
CAS
Google Scholar
Lv JW, Qi ZY, Zhou GQ, He XJ, Chen YP, Mao YP, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. Cancer Sci. 2018;109(3):751–63.
Article
CAS
Google Scholar
Chen BB, Lu SY, Peng H, Sun FF, Zhu J, Wang J, et al. Comparison of long-term outcomes and sequelae between children and adult nasopharyngeal carcinoma treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2020;106(4):848–56.
Article
Google Scholar
Downing NL, Wolden S, Wong P, Petrik DW, Hara W, Le QT. Comparison of treatment results between adult and juvenile nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009;75(4):1064–70.
Article
Google Scholar
Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20.
Article
CAS
Google Scholar
Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23.
Article
CAS
Google Scholar
Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What Is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35(5):498–505.
Article
Google Scholar
Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, et al. The prognostic value of plasma Epstein–Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–9.
Article
CAS
Google Scholar
Peng H, Chen L, Zhang Y, Li WF, Mao YP, Liu X, et al. The tumour response to induction chemotherapy has prognostic value for long-term survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma. Sci Rep. 2016;6:24835.
Article
CAS
Google Scholar
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.
Article
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
Article
CAS
Google Scholar
Coy HJ, Douek ML, Ruchalski K, Kim HJ, Gutierrez A, Patel M, et al. Components of radiologic progressive disease defined by RECIST 1.1 in patients with metastatic clear cell renal cell carcinoma. Radiology. 2019;292(1):103–9.
Article
Google Scholar
Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883–92.
Article
CAS
Google Scholar
Yao JJ, Zhang F, Gao TS, Zhang WJ, Lawrence WR, Zhu BT, et al. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Radiother Oncol. 2019;132:178–87.
Article
Google Scholar
Yao JJ, Lin L, Jin YN, Wang SY, Zhang WJ, Zhang F, et al. Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA. Cancer Sci. 2017;108(8):1640–7.
Article
CAS
Google Scholar
Yao JJ, Zhou GQ, Wang YQ, Wang SY, Zhang WJ, Jin YN, et al. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein–Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. Chin J Cancer. 2017;36(1):98.
Article
Google Scholar
Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):300–4.
Article
CAS
Google Scholar
Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol. 2018;29(9):1972–9.
Article
CAS
Google Scholar
Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res. 2018;24(8):1824–33.
Article
CAS
Google Scholar
Casanova M, Bisogno G, Gandola L, Cecchetto G, Di Cataldo A, Basso E, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. Cancer. 2012;118(10):2718–25.
Article
Google Scholar
Casanova M, Özyar E, Patte C, Orbach D, Ferrari A, Veyrat-Follet C, et al. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemother Pharmacol. 2016;77(2):289–98.
Article
CAS
Google Scholar
Buehrlen M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012;118(19):4892–900.
Article
CAS
Google Scholar
Sahai P, Mohanti BK, Sharma A, Thakar A, Bhasker S, Kakkar A, et al. Clinical outcome and morbidity in pediatric patients with nasopharyngeal cancer treated with chemoradiotherapy. Pediatr Blood Cancer. 2017;64(2):259–66.
Article
CAS
Google Scholar
Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, et al. Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: results of the children’s oncology group ARAR0331 study. J Clin Oncol. 2019;37(35):3369–76.
Article
CAS
Google Scholar
Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242–9.
Article
CAS
Google Scholar
Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–35.
Article
CAS
Google Scholar
Tang C, Wu F, Wang R, Lu H, Li G, Liu M, et al. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial. Am J Cancer Res. 2016;6(9):2064–75.
CAS
PubMed
PubMed Central
Google Scholar
Liu SL, Sun XS, Yan JJ, Chen QY, Lin HX, Wen YF, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. Radiother Oncol. 2019;137:83–94.
Article
CAS
Google Scholar
Yao JJ, Qi ZY, Liu ZG, Jiang GM, Xu XW, Chen SY, et al. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Radiother Oncol. 2019;137:137–44.
Article
Google Scholar
Mertens R, Granzen B, Lassay L, Gademann G, Hess CF, Heimann G. Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Gesellschaft für Pädiatrische Onkologie und Hämatologie. Cancer. 1997;80(5):951–9.
Article
CAS
Google Scholar